| 
																	
																	
																		 Kevin Deane
 
																		 Concepts  (465)
																		
																	 
																		Concepts are derived automatically from a person's publications. 
																			
																					
    Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
     | Name | Number of Publications | Most Recent Publication | Publications by All Authors | Concept Score | Why? | 
|---|
 | Arthritis, Rheumatoid | 120 | 2025 | 1159 | 18.780 | Why? |  | Autoantibodies | 66 | 2025 | 1498 | 7.910 | Why? |  | Anti-Citrullinated Protein Antibodies | 27 | 2025 | 113 | 6.290 | Why? |  | Rheumatoid Factor | 39 | 2025 | 173 | 5.630 | Why? |  | Peptides, Cyclic | 30 | 2025 | 260 | 3.500 | Why? |  | Autoimmunity | 23 | 2025 | 893 | 3.280 | Why? |  | Antirheumatic Agents | 12 | 2025 | 290 | 2.630 | Why? |  | Rheumatic Diseases | 4 | 2022 | 80 | 1.750 | Why? |  | Sputum | 5 | 2025 | 310 | 1.690 | Why? |  | Methotrexate | 5 | 2025 | 255 | 1.570 | Why? |  | Lung Diseases, Interstitial | 10 | 2025 | 631 | 1.260 | Why? |  | Humans | 156 | 2025 | 136899 | 1.210 | Why? |  | Biomarkers | 30 | 2025 | 4148 | 1.180 | Why? |  | Immunoglobulin A | 11 | 2023 | 208 | 1.160 | Why? |  | HIV Infections | 5 | 2023 | 2822 | 1.140 | Why? |  | Autoimmune Diseases | 5 | 2024 | 459 | 1.120 | Why? |  | Autoantigens | 8 | 2023 | 429 | 1.000 | Why? |  | Disease Progression | 17 | 2025 | 2744 | 0.970 | Why? |  | Malaria | 2 | 2025 | 64 | 0.940 | Why? |  | Bronchial Diseases | 3 | 2013 | 37 | 0.880 | Why? |  | Early Medical Intervention | 2 | 2014 | 58 | 0.870 | Why? |  | Extracellular Traps | 3 | 2021 | 53 | 0.850 | Why? |  | Genetic Predisposition to Disease | 16 | 2023 | 2416 | 0.830 | Why? |  | Inflammation | 10 | 2024 | 2817 | 0.820 | Why? |  | Female | 94 | 2025 | 72703 | 0.820 | Why? |  | Male | 81 | 2025 | 67308 | 0.810 | Why? |  | Mucous Membrane | 2 | 2024 | 125 | 0.770 | Why? |  | Lung Diseases | 4 | 2022 | 768 | 0.770 | Why? |  | Middle Aged | 70 | 2025 | 33118 | 0.770 | Why? |  | Risk Factors | 31 | 2025 | 10313 | 0.760 | Why? |  | Rheumatology | 6 | 2021 | 119 | 0.760 | Why? |  | Early Diagnosis | 8 | 2022 | 243 | 0.760 | Why? |  | Mosquito Vectors | 1 | 2022 | 26 | 0.750 | Why? |  | Insecticides | 1 | 2022 | 38 | 0.740 | Why? |  | Acquired Immunodeficiency Syndrome | 1 | 2023 | 233 | 0.730 | Why? |  | Case-Control Studies | 19 | 2025 | 3528 | 0.720 | Why? |  | Lupus Erythematosus, Systemic | 4 | 2022 | 256 | 0.720 | Why? |  | Precision Medicine | 3 | 2020 | 413 | 0.720 | Why? |  | Arthralgia | 2 | 2021 | 53 | 0.710 | Why? |  | Joints | 4 | 2015 | 105 | 0.710 | Why? |  | Prodromal Symptoms | 1 | 2020 | 15 | 0.700 | Why? |  | Epitopes | 8 | 2023 | 479 | 0.680 | Why? |  | Sexual and Gender Minorities | 1 | 2023 | 210 | 0.630 | Why? |  | Citrullination | 2 | 2020 | 13 | 0.630 | Why? |  | Adult | 55 | 2025 | 37595 | 0.610 | Why? |  | Histones | 4 | 2023 | 639 | 0.610 | Why? |  | Lung | 7 | 2020 | 4046 | 0.610 | Why? |  | Enzyme-Linked Immunosorbent Assay | 6 | 2023 | 849 | 0.610 | Why? |  | Aged | 41 | 2025 | 23641 | 0.580 | Why? |  | Pre-Exposure Prophylaxis | 1 | 2020 | 213 | 0.570 | Why? |  | Asymptomatic Diseases | 2 | 2021 | 87 | 0.550 | Why? |  | Transgender Persons | 1 | 2020 | 179 | 0.550 | Why? |  | Immunoglobulin G | 11 | 2023 | 886 | 0.550 | Why? |  | Pedigree | 2 | 2020 | 509 | 0.540 | Why? |  | Synovitis | 2 | 2023 | 27 | 0.520 | Why? |  | Citrulline | 2 | 2016 | 45 | 0.520 | Why? |  | Qualitative Research | 5 | 2024 | 1335 | 0.520 | Why? |  | Antibodies, Anti-Idiotypic | 2 | 2015 | 59 | 0.510 | Why? |  | Human Migration | 1 | 2016 | 23 | 0.510 | Why? |  | Transients and Migrants | 1 | 2016 | 27 | 0.500 | Why? |  | Rituximab | 3 | 2025 | 172 | 0.500 | Why? |  | Synovial Membrane | 4 | 2025 | 117 | 0.500 | Why? |  | Arthritis | 2 | 2016 | 95 | 0.490 | Why? |  | Immunoglobulin M | 7 | 2023 | 287 | 0.470 | Why? |  | Prospective Studies | 21 | 2025 | 7543 | 0.460 | Why? |  | Th17 Cells | 3 | 2025 | 99 | 0.460 | Why? |  | Abatacept | 2 | 2025 | 53 | 0.450 | Why? |  | Patient Acceptance of Health Care | 1 | 2020 | 798 | 0.440 | Why? |  | Cytokines | 10 | 2023 | 2078 | 0.440 | Why? |  | Sexual Behavior | 2 | 2016 | 487 | 0.430 | Why? |  | Family | 7 | 2021 | 667 | 0.430 | Why? |  | Pneumonia | 1 | 2020 | 631 | 0.430 | Why? |  | Antipsychotic Agents | 1 | 2016 | 196 | 0.430 | Why? |  | Psychotic Disorders | 1 | 2016 | 166 | 0.420 | Why? |  | Endothelium, Vascular | 4 | 2013 | 922 | 0.410 | Why? |  | Risk-Taking | 1 | 2016 | 354 | 0.410 | Why? |  | Chemokines | 2 | 2012 | 229 | 0.410 | Why? |  | HSP90 Heat-Shock Proteins | 1 | 2013 | 47 | 0.400 | Why? |  | Hydroxychloroquine | 2 | 2025 | 59 | 0.400 | Why? |  | Risk Reduction Behavior | 1 | 2014 | 219 | 0.390 | Why? |  | Tanzania | 3 | 2021 | 57 | 0.390 | Why? |  | Hazardous Substances | 1 | 2012 | 17 | 0.390 | Why? |  | Observational Studies as Topic | 2 | 2024 | 115 | 0.380 | Why? |  | Susac Syndrome | 1 | 2011 | 3 | 0.360 | Why? |  | Fatty Acids, Omega-3 | 3 | 2017 | 138 | 0.350 | Why? |  | Gene-Environment Interaction | 1 | 2012 | 193 | 0.340 | Why? |  | B-Lymphocytes | 3 | 2025 | 844 | 0.340 | Why? |  | Pregnancy Complications, Cardiovascular | 1 | 2011 | 81 | 0.340 | Why? |  | Smoking | 9 | 2024 | 1633 | 0.340 | Why? |  | Social Stigma | 2 | 2023 | 132 | 0.340 | Why? |  | Mass Screening | 3 | 2020 | 1262 | 0.340 | Why? |  | Emigration and Immigration | 1 | 2010 | 50 | 0.340 | Why? |  | Mucin-5B | 3 | 2025 | 224 | 0.340 | Why? |  | Risk Assessment | 7 | 2025 | 3432 | 0.330 | Why? |  | Malondialdehyde | 2 | 2020 | 29 | 0.330 | Why? |  | Protein Processing, Post-Translational | 1 | 2013 | 471 | 0.330 | Why? |  | Acetaldehyde | 2 | 2020 | 17 | 0.330 | Why? |  | Health Fairs | 1 | 2009 | 9 | 0.330 | Why? |  | Antibodies, Antinuclear | 5 | 2023 | 70 | 0.330 | Why? |  | Postmenopause | 7 | 2023 | 361 | 0.330 | Why? |  | Research Design | 3 | 2024 | 1108 | 0.330 | Why? |  | Glucocorticoids | 3 | 2021 | 596 | 0.300 | Why? |  | Antibodies, Bacterial | 3 | 2023 | 146 | 0.300 | Why? |  | Tumor Necrosis Factor-alpha | 4 | 2025 | 1242 | 0.300 | Why? |  | Clinical Trials as Topic | 2 | 2025 | 1037 | 0.290 | Why? |  | Incidence | 9 | 2021 | 2783 | 0.290 | Why? |  | Focus Groups | 2 | 2024 | 500 | 0.280 | Why? |  | Health Behavior | 3 | 2018 | 761 | 0.270 | Why? |  | B-Cell Activating Factor | 2 | 2024 | 21 | 0.270 | Why? |  | Chlamydia trachomatis | 2 | 2025 | 48 | 0.260 | Why? |  | Cross-Sectional Studies | 9 | 2023 | 5398 | 0.250 | Why? |  | Antibody Formation | 4 | 2023 | 299 | 0.250 | Why? |  | Immunophenotyping | 2 | 2025 | 318 | 0.250 | Why? |  | Antibodies, Antiphospholipid | 1 | 2005 | 28 | 0.240 | Why? |  | Chlamydia Infections | 2 | 2025 | 74 | 0.240 | Why? |  | Qa-SNARE Proteins | 1 | 2025 | 20 | 0.240 | Why? |  | Developing Countries | 2 | 2025 | 305 | 0.240 | Why? |  | Vasculitis | 1 | 2005 | 65 | 0.240 | Why? |  | HLA-B27 Antigen | 1 | 2024 | 16 | 0.230 | Why? |  | Arthritis, Psoriatic | 1 | 2024 | 21 | 0.230 | Why? |  | Complement Factor H | 1 | 2025 | 75 | 0.220 | Why? |  | Longitudinal Studies | 5 | 2025 | 2844 | 0.220 | Why? |  | Complement Activation | 2 | 2025 | 412 | 0.220 | Why? |  | Spondylarthritis | 1 | 2024 | 47 | 0.220 | Why? |  | Animals | 11 | 2025 | 36915 | 0.210 | Why? |  | Clinical Decision-Making | 2 | 2024 | 320 | 0.210 | Why? |  | Likelihood Functions | 1 | 2024 | 143 | 0.210 | Why? |  | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2024 | 73 | 0.210 | Why? |  | Polysaccharides | 2 | 2017 | 87 | 0.210 | Why? |  | Risk | 3 | 2016 | 905 | 0.210 | Why? |  | T-Lymphocytes, Helper-Inducer | 1 | 2024 | 137 | 0.210 | Why? |  | Estrogens | 3 | 2017 | 358 | 0.210 | Why? |  | London | 1 | 2023 | 47 | 0.210 | Why? |  | Africa South of the Sahara | 1 | 2023 | 48 | 0.210 | Why? |  | HLA-DR Antigens | 1 | 2024 | 228 | 0.200 | Why? |  | Protein-Arginine Deiminases | 3 | 2021 | 16 | 0.200 | Why? |  | Time Factors | 6 | 2019 | 6802 | 0.200 | Why? |  | Down-Regulation | 1 | 2025 | 658 | 0.200 | Why? |  | Autophagy | 1 | 2025 | 282 | 0.200 | Why? |  | Immunoglobulin Isotypes | 1 | 2022 | 34 | 0.200 | Why? |  | Patient Education as Topic | 3 | 2018 | 762 | 0.200 | Why? |  | Periodontal Diseases | 1 | 2023 | 60 | 0.200 | Why? |  | Mouth Mucosa | 3 | 2023 | 92 | 0.200 | Why? |  | Trichloroethylene | 1 | 2022 | 8 | 0.200 | Why? |  | Transforming Growth Factor beta | 1 | 2025 | 480 | 0.190 | Why? |  | Insecticide-Treated Bednets | 1 | 2022 | 6 | 0.190 | Why? |  | Gender Identity | 1 | 2023 | 124 | 0.190 | Why? |  | Homosexuality, Male | 1 | 2023 | 182 | 0.190 | Why? |  | Policy | 1 | 2023 | 150 | 0.190 | Why? |  | Biological Products | 2 | 2022 | 219 | 0.180 | Why? |  | Blood Platelets | 1 | 2025 | 405 | 0.180 | Why? |  | Leukocytes, Mononuclear | 3 | 2024 | 557 | 0.180 | Why? |  | Social Determinants of Health | 1 | 2025 | 246 | 0.180 | Why? |  | CD8-Positive T-Lymphocytes | 2 | 2025 | 916 | 0.180 | Why? |  | Pulmonary Fibrosis | 1 | 2025 | 397 | 0.180 | Why? |  | Prevalence | 4 | 2022 | 2709 | 0.180 | Why? |  | Young Adult | 9 | 2021 | 13157 | 0.180 | Why? |  | Women's Health | 5 | 2017 | 371 | 0.180 | Why? |  | Sex Factors | 5 | 2020 | 2067 | 0.180 | Why? |  | Organ Specificity | 2 | 2019 | 304 | 0.180 | Why? |  | Hemorrhage | 1 | 2005 | 718 | 0.180 | Why? |  | Lymphocyte Activation | 1 | 2025 | 1150 | 0.170 | Why? |  | Neutrophil Activation | 1 | 2021 | 81 | 0.170 | Why? |  | Fatty Acids, Unsaturated | 1 | 2021 | 98 | 0.170 | Why? |  | Housing | 1 | 2022 | 145 | 0.170 | Why? |  | Epstein-Barr Virus Infections | 1 | 2022 | 99 | 0.170 | Why? |  | Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2020 | 8 | 0.170 | Why? |  | Sarcoidosis | 1 | 2022 | 159 | 0.170 | Why? |  | Chemokine CXCL16 | 1 | 2020 | 4 | 0.170 | Why? |  | Museums | 1 | 2000 | 11 | 0.170 | Why? |  | Cytomegalovirus Infections | 1 | 2022 | 194 | 0.160 | Why? |  | Intestines | 2 | 2021 | 356 | 0.160 | Why? |  | Severity of Illness Index | 8 | 2022 | 2833 | 0.160 | Why? |  | Muramidase | 1 | 2020 | 77 | 0.160 | Why? |  | Complement System Proteins | 2 | 2022 | 328 | 0.160 | Why? |  | Sjogren's Syndrome | 1 | 2020 | 54 | 0.160 | Why? |  | Public-Private Sector Partnerships | 1 | 2020 | 43 | 0.160 | Why? |  | Toll-Like Receptors | 1 | 2020 | 186 | 0.160 | Why? |  | Art Therapy | 1 | 2000 | 19 | 0.160 | Why? |  | Bacteriophages | 1 | 2021 | 94 | 0.160 | Why? |  | United Kingdom | 1 | 2020 | 322 | 0.160 | Why? |  | Lipopolysaccharide Receptors | 1 | 2020 | 86 | 0.160 | Why? |  | Retrospective Studies | 5 | 2024 | 15514 | 0.160 | Why? |  | Attitude | 1 | 2021 | 260 | 0.160 | Why? |  | Nuclear Family | 1 | 2019 | 54 | 0.150 | Why? |  | Age Factors | 7 | 2020 | 3290 | 0.150 | Why? |  | Inflammation Mediators | 2 | 2020 | 514 | 0.150 | Why? |  | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2016 | 46 | 0.150 | Why? |  | Gain of Function Mutation | 1 | 2018 | 35 | 0.150 | Why? |  | CD4-Positive T-Lymphocytes | 1 | 2025 | 1092 | 0.150 | Why? |  | Mitochondria | 2 | 2025 | 938 | 0.150 | Why? |  | Arthritis, Experimental | 1 | 2020 | 143 | 0.150 | Why? |  | Gene Expression | 2 | 2022 | 1505 | 0.150 | Why? |  | Multiple Sclerosis | 1 | 2024 | 451 | 0.150 | Why? |  | Dexamethasone | 1 | 2020 | 374 | 0.150 | Why? |  | Occupational Exposure | 1 | 2022 | 342 | 0.150 | Why? |  | Proteomics | 1 | 2025 | 1111 | 0.150 | Why? |  | Monocytes | 1 | 2020 | 567 | 0.140 | Why? |  | HLA-DR4 Antigen | 3 | 2007 | 78 | 0.140 | Why? |  | Cohort Studies | 10 | 2022 | 5711 | 0.140 | Why? |  | Cellular Senescence | 1 | 2019 | 188 | 0.140 | Why? |  | Military Personnel | 2 | 2021 | 540 | 0.140 | Why? |  | Vascular Stiffness | 2 | 2013 | 484 | 0.140 | Why? |  | Metabolome | 1 | 2020 | 349 | 0.140 | Why? |  | Remission Induction | 2 | 2021 | 286 | 0.140 | Why? |  | Galactose | 1 | 2017 | 33 | 0.130 | Why? |  | Global Health | 1 | 2020 | 384 | 0.130 | Why? |  | Decision Making | 1 | 2024 | 897 | 0.130 | Why? |  | Glycosylation | 1 | 2017 | 162 | 0.130 | Why? |  | Seroepidemiologic Studies | 3 | 2014 | 163 | 0.130 | Why? |  | Coronary Disease | 2 | 2017 | 385 | 0.130 | Why? |  | Sex Work | 1 | 2016 | 22 | 0.130 | Why? |  | Adiponectin | 1 | 2018 | 241 | 0.130 | Why? |  | Plasma Cells | 1 | 2016 | 71 | 0.130 | Why? |  | United States | 8 | 2022 | 14595 | 0.130 | Why? |  | Hydrolases | 2 | 2021 | 56 | 0.130 | Why? |  | Estradiol | 3 | 2017 | 513 | 0.130 | Why? |  | HLA Antigens | 1 | 2017 | 237 | 0.120 | Why? |  | Respiratory Function Tests | 3 | 2025 | 596 | 0.120 | Why? |  | Sensitivity and Specificity | 3 | 2018 | 1945 | 0.120 | Why? |  | Diagnosis, Differential | 3 | 2013 | 1484 | 0.120 | Why? |  | Idiopathic Pulmonary Fibrosis | 2 | 2019 | 652 | 0.120 | Why? |  | Mothers | 1 | 2021 | 752 | 0.120 | Why? |  | Neutrophils | 1 | 2021 | 1237 | 0.120 | Why? |  | Peptides | 1 | 2021 | 981 | 0.120 | Why? |  | Diet | 2 | 2020 | 1261 | 0.120 | Why? |  | Tertiary Prevention | 1 | 2014 | 3 | 0.120 | Why? |  | Adaptation, Psychological | 1 | 2000 | 644 | 0.110 | Why? |  | Vasodilation | 3 | 2013 | 494 | 0.110 | Why? |  | Cardiovascular Diseases | 3 | 2017 | 2110 | 0.110 | Why? |  | C-Reactive Protein | 5 | 2018 | 409 | 0.110 | Why? |  | Drug Therapy, Combination | 2 | 2021 | 1060 | 0.110 | Why? |  | Alcohol Drinking | 1 | 2020 | 823 | 0.110 | Why? |  | Neoplasms | 2 | 2017 | 2655 | 0.100 | Why? |  | Secondary Prevention | 1 | 2014 | 229 | 0.100 | Why? |  | Socioeconomic Factors | 3 | 2025 | 1279 | 0.100 | Why? |  | Respiratory Mucosa | 1 | 2016 | 322 | 0.100 | Why? |  | Blood Pressure | 2 | 2017 | 1774 | 0.100 | Why? |  | Bacteroidaceae Infections | 1 | 2012 | 7 | 0.100 | Why? |  | Receptors, Tumor Necrosis Factor | 1 | 2013 | 164 | 0.100 | Why? |  | Porphyromonas gingivalis | 1 | 2012 | 23 | 0.100 | Why? |  | Primary Prevention | 1 | 2014 | 195 | 0.100 | Why? |  | Family Health | 2 | 2013 | 200 | 0.100 | Why? |  | Tomography, X-Ray Computed | 4 | 2025 | 2670 | 0.100 | Why? |  | Delivery of Health Care | 1 | 2020 | 948 | 0.100 | Why? |  | Vitamin D | 2 | 2022 | 392 | 0.100 | Why? |  | Immune Tolerance | 1 | 2014 | 362 | 0.100 | Why? |  | Periodontitis | 1 | 2012 | 52 | 0.100 | Why? |  | Communicable Disease Control | 2 | 2024 | 82 | 0.100 | Why? |  | Health | 1 | 2012 | 84 | 0.100 | Why? |  | Arthrography | 1 | 2011 | 17 | 0.100 | Why? |  | Stress, Psychological | 1 | 2020 | 1112 | 0.100 | Why? |  | Population Surveillance | 1 | 2015 | 471 | 0.090 | Why? |  | Telomere Shortening | 2 | 2024 | 20 | 0.090 | Why? |  | Pneumonia, Bacterial | 1 | 2013 | 117 | 0.090 | Why? |  | Delayed Diagnosis | 1 | 2012 | 91 | 0.090 | Why? |  | RNA, Messenger | 3 | 2025 | 2837 | 0.090 | Why? |  | Predictive Value of Tests | 3 | 2013 | 2030 | 0.090 | Why? |  | Disease Susceptibility | 3 | 2021 | 344 | 0.090 | Why? |  | Proportional Hazards Models | 3 | 2021 | 1262 | 0.090 | Why? |  | Asthma | 1 | 2024 | 2285 | 0.090 | Why? |  | Breast Neoplasms | 1 | 2023 | 2243 | 0.090 | Why? |  | Labor, Induced | 1 | 2011 | 32 | 0.090 | Why? |  | Logistic Models | 5 | 2020 | 2060 | 0.090 | Why? |  | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 88 | 0.090 | Why? |  | Follow-Up Studies | 4 | 2019 | 5126 | 0.090 | Why? |  | Time-to-Treatment | 1 | 2012 | 200 | 0.090 | Why? |  | Phenotype | 4 | 2023 | 3201 | 0.090 | Why? |  | Cyclophosphamide | 1 | 2011 | 246 | 0.080 | Why? |  | Reproducibility of Results | 3 | 2020 | 3282 | 0.080 | Why? |  | Immunoglobulins, Intravenous | 1 | 2011 | 132 | 0.080 | Why? |  | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1324 | 0.080 | Why? |  | Vasodilator Agents | 1 | 2012 | 333 | 0.080 | Why? |  | Statistics, Nonparametric | 1 | 2010 | 434 | 0.080 | Why? |  | Menopause | 1 | 2012 | 315 | 0.080 | Why? |  | Respiratory Insufficiency | 1 | 2013 | 316 | 0.080 | Why? |  | Colorado | 3 | 2020 | 4491 | 0.080 | Why? |  | Air Pollution | 1 | 2013 | 315 | 0.080 | Why? |  | Community-Institutional Relations | 1 | 2009 | 99 | 0.080 | Why? |  | Aging | 1 | 2019 | 1863 | 0.080 | Why? |  | Treatment Outcome | 3 | 2021 | 10768 | 0.070 | Why? |  | Interleukin-6 | 3 | 2021 | 771 | 0.070 | Why? |  | Odds Ratio | 3 | 2018 | 1063 | 0.070 | Why? |  | Alleles | 3 | 2019 | 888 | 0.070 | Why? |  | Aspirin | 1 | 2011 | 385 | 0.070 | Why? |  | Colposcopy | 1 | 2007 | 17 | 0.070 | Why? |  | Disease Outbreaks | 1 | 2010 | 374 | 0.070 | Why? |  | Obesity | 1 | 2020 | 2966 | 0.070 | Why? |  | Adrenal Cortex Hormones | 1 | 2011 | 552 | 0.070 | Why? |  | Brachial Artery | 3 | 2013 | 200 | 0.070 | Why? |  | Societies, Medical | 2 | 2021 | 816 | 0.070 | Why? |  | Stroke | 1 | 2015 | 1122 | 0.070 | Why? |  | Contraceptives, Oral, Hormonal | 1 | 2006 | 34 | 0.060 | Why? |  | Mice | 4 | 2025 | 17775 | 0.060 | Why? |  | Capillaries | 1 | 2005 | 108 | 0.060 | Why? |  | Switzerland | 1 | 2025 | 38 | 0.060 | Why? |  | Environment | 2 | 2019 | 362 | 0.060 | Why? |  | Premenopause | 2 | 2017 | 125 | 0.060 | Why? |  | Radiography, Thoracic | 1 | 2005 | 168 | 0.060 | Why? |  | Healthy Volunteers | 2 | 2017 | 204 | 0.060 | Why? |  | Bronchoscopy | 1 | 2005 | 222 | 0.060 | Why? |  | Arthritis, Juvenile | 1 | 2005 | 55 | 0.060 | Why? |  | Receptors, CXCR5 | 1 | 2024 | 21 | 0.060 | Why? |  | Pregnancy | 2 | 2021 | 6715 | 0.050 | Why? |  | Uganda | 1 | 2024 | 72 | 0.050 | Why? |  | Quarantine | 1 | 2024 | 29 | 0.050 | Why? |  | Immunity, Mucosal | 2 | 2014 | 97 | 0.050 | Why? |  | Phosphopyruvate Hydratase | 1 | 2023 | 26 | 0.050 | Why? |  | Aged, 80 and over | 3 | 2024 | 7552 | 0.050 | Why? |  | Interleukin-2 | 2 | 2016 | 455 | 0.050 | Why? |  | Pulmonary Alveoli | 1 | 2005 | 405 | 0.050 | Why? |  | Vimentin | 1 | 2023 | 52 | 0.050 | Why? |  | Antibodies | 1 | 2005 | 414 | 0.050 | Why? |  | Employment | 1 | 2024 | 177 | 0.050 | Why? |  | Biopsy | 1 | 2005 | 1130 | 0.050 | Why? |  | Multivariate Analysis | 2 | 2021 | 1524 | 0.050 | Why? |  | Immunoglobulins | 2 | 2015 | 171 | 0.050 | Why? |  | Tissue Distribution | 1 | 2022 | 330 | 0.050 | Why? |  | Body Mass Index | 2 | 2020 | 2351 | 0.050 | Why? |  | Hydroxyeicosatetraenoic Acids | 1 | 2021 | 43 | 0.040 | Why? |  | Poverty | 1 | 2025 | 519 | 0.040 | Why? |  | Surveys and Questionnaires | 2 | 2014 | 5730 | 0.040 | Why? |  | Janus Kinase Inhibitors | 1 | 2021 | 26 | 0.040 | Why? |  | Carotid Arteries | 2 | 2013 | 206 | 0.040 | Why? |  | Putrescine | 1 | 2020 | 2 | 0.040 | Why? |  | Butyric Acid | 1 | 2020 | 7 | 0.040 | Why? |  | Xenobiotics | 1 | 2021 | 32 | 0.040 | Why? |  | Herpesvirus 4, Human | 1 | 2022 | 167 | 0.040 | Why? |  | Vitamins | 1 | 2022 | 176 | 0.040 | Why? |  | Genetic Markers | 1 | 2022 | 345 | 0.040 | Why? |  | Urban Population | 1 | 2024 | 470 | 0.040 | Why? |  | Telomere | 1 | 2024 | 280 | 0.040 | Why? |  | Spermidine | 1 | 2020 | 19 | 0.040 | Why? |  | Caprylates | 1 | 2020 | 25 | 0.040 | Why? |  | Immunosuppressive Agents | 1 | 2005 | 886 | 0.040 | Why? |  | Interviews as Topic | 1 | 2024 | 759 | 0.040 | Why? |  | Docosahexaenoic Acids | 1 | 2021 | 83 | 0.040 | Why? |  | Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2020 | 4 | 0.040 | Why? |  | Phosphatidylethanolamines | 1 | 2020 | 77 | 0.040 | Why? |  | Chemokine CXCL13 | 1 | 2020 | 8 | 0.040 | Why? |  | Europe | 1 | 2021 | 413 | 0.040 | Why? |  | Chemokine CXCL9 | 1 | 2020 | 27 | 0.040 | Why? |  | Synovial Fluid | 1 | 2020 | 69 | 0.040 | Why? |  | Survival Analysis | 2 | 2017 | 1320 | 0.040 | Why? |  | Carnitine | 1 | 2020 | 83 | 0.040 | Why? |  | Microbiota | 2 | 2021 | 763 | 0.040 | Why? |  | RNA, Viral | 1 | 2024 | 651 | 0.040 | Why? |  | Acute-Phase Proteins | 1 | 2020 | 67 | 0.040 | Why? |  | Flow Cytometry | 1 | 2024 | 1185 | 0.040 | Why? |  | Chemokine CXCL10 | 1 | 2020 | 39 | 0.040 | Why? |  | Interleukin-8 | 1 | 2021 | 269 | 0.040 | Why? |  | Methionine | 1 | 2020 | 159 | 0.040 | Why? |  | Anxiety | 1 | 2007 | 1039 | 0.040 | Why? |  | Fluorescent Antibody Technique | 1 | 2020 | 386 | 0.040 | Why? |  | Interleukin-1alpha | 1 | 2020 | 58 | 0.040 | Why? |  | Child Health | 1 | 2021 | 155 | 0.040 | Why? |  | Antibody Specificity | 1 | 2020 | 189 | 0.040 | Why? |  | Interinstitutional Relations | 1 | 2000 | 54 | 0.040 | Why? |  | Ontario | 1 | 2000 | 156 | 0.040 | Why? |  | Disease Models, Animal | 1 | 2010 | 4281 | 0.040 | Why? |  | Rural Population | 1 | 2024 | 561 | 0.040 | Why? |  | Baltimore | 1 | 2019 | 58 | 0.040 | Why? |  | International Cooperation | 1 | 2020 | 198 | 0.040 | Why? |  | Tryptophan | 1 | 2020 | 183 | 0.040 | Why? |  | Endotoxins | 1 | 2020 | 220 | 0.040 | Why? |  | Interleukin-1beta | 1 | 2021 | 371 | 0.040 | Why? |  | Genotype | 2 | 2018 | 1906 | 0.040 | Why? |  | Prognosis | 2 | 2021 | 4011 | 0.040 | Why? |  | Interferons | 1 | 2020 | 199 | 0.040 | Why? |  | Receptors, Antigen, T-Cell | 1 | 2023 | 719 | 0.040 | Why? |  | Epitopes, B-Lymphocyte | 1 | 2018 | 17 | 0.040 | Why? |  | Dysbiosis | 1 | 2020 | 179 | 0.040 | Why? |  | Interleukins | 1 | 2020 | 251 | 0.040 | Why? |  | Mice, Knockout | 1 | 2025 | 2998 | 0.040 | Why? |  | Forecasting | 1 | 2020 | 386 | 0.040 | Why? |  | Reactive Oxygen Species | 1 | 2021 | 619 | 0.040 | Why? |  | Consensus | 1 | 2021 | 678 | 0.040 | Why? |  | Nurses | 1 | 2020 | 174 | 0.040 | Why? |  | Tobacco Products | 1 | 2019 | 139 | 0.040 | Why? |  | Gene Frequency | 1 | 2019 | 521 | 0.040 | Why? |  | Antibodies, Viral | 1 | 2022 | 620 | 0.040 | Why? |  | Gene Regulatory Networks | 1 | 2020 | 307 | 0.030 | Why? |  | Genetic Testing | 1 | 2020 | 453 | 0.030 | Why? |  | Polymorphism, Single Nucleotide | 2 | 2019 | 2175 | 0.030 | Why? |  | Goserelin | 1 | 2017 | 7 | 0.030 | Why? |  | Biomarkers, Tumor | 1 | 2024 | 1271 | 0.030 | Why? |  | Membrane Glycoproteins | 1 | 2020 | 501 | 0.030 | Why? |  | Amino Acids | 1 | 2021 | 503 | 0.030 | Why? |  | Fertility Agents, Female | 1 | 2017 | 20 | 0.030 | Why? |  | Raloxifene Hydrochloride | 1 | 2017 | 16 | 0.030 | Why? |  | Decision Support Techniques | 1 | 2021 | 413 | 0.030 | Why? |  | Selective Estrogen Receptor Modulators | 1 | 2017 | 29 | 0.030 | Why? |  | Phylogeny | 1 | 2021 | 897 | 0.030 | Why? |  | Leuprolide | 1 | 2017 | 19 | 0.030 | Why? |  | Genes, Immunoglobulin Light Chain | 1 | 2016 | 5 | 0.030 | Why? |  | Genes, Immunoglobulin Heavy Chain | 1 | 2016 | 10 | 0.030 | Why? |  | Phosphofructokinase-2 | 1 | 2016 | 15 | 0.030 | Why? |  | Aromatase Inhibitors | 1 | 2017 | 53 | 0.030 | Why? |  | Estrogens, Conjugated (USP) | 1 | 2017 | 48 | 0.030 | Why? |  | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 67 | 0.030 | Why? |  | Bacteria | 1 | 2023 | 855 | 0.030 | Why? |  | Protective Factors | 1 | 2016 | 94 | 0.030 | Why? |  | Models, Statistical | 1 | 2020 | 667 | 0.030 | Why? |  | Carrier Proteins | 1 | 2020 | 770 | 0.030 | Why? |  | Antibodies, Monoclonal | 1 | 2022 | 1417 | 0.030 | Why? |  | Health Education | 1 | 2018 | 343 | 0.030 | Why? |  | Patient Satisfaction | 1 | 2000 | 657 | 0.030 | Why? |  | Gonadotropin-Releasing Hormone | 1 | 2017 | 206 | 0.030 | Why? |  | Androgens | 1 | 2017 | 188 | 0.030 | Why? |  | Symptom Assessment | 1 | 2016 | 126 | 0.030 | Why? |  | Adolescent | 4 | 2021 | 21402 | 0.030 | Why? |  | T-Lymphocytes | 1 | 2023 | 1996 | 0.030 | Why? |  | Pandemics | 1 | 2024 | 1615 | 0.030 | Why? |  | Leukocyte Count | 1 | 2015 | 331 | 0.030 | Why? |  | Transcriptome | 1 | 2021 | 973 | 0.030 | Why? |  | Hypercholesterolemia | 1 | 2015 | 103 | 0.030 | Why? |  | Promoter Regions, Genetic | 1 | 2018 | 1255 | 0.030 | Why? |  | Etanercept | 1 | 2013 | 57 | 0.030 | Why? |  | HLA-DRB1 Chains | 1 | 2014 | 112 | 0.030 | Why? |  | Sequence Analysis, DNA | 1 | 2016 | 811 | 0.030 | Why? |  | Testosterone | 1 | 2017 | 398 | 0.030 | Why? |  | Motivation | 1 | 2018 | 570 | 0.030 | Why? |  | Pneumocystis carinii | 1 | 2013 | 11 | 0.030 | Why? |  | Geographic Information Systems | 1 | 2013 | 43 | 0.030 | Why? |  | Oral Health | 1 | 2014 | 124 | 0.030 | Why? |  | High-Throughput Nucleotide Sequencing | 1 | 2016 | 536 | 0.020 | Why? |  | Interleukin-9 | 1 | 2012 | 9 | 0.020 | Why? |  | Communication | 1 | 2018 | 872 | 0.020 | Why? |  | Cell Membrane | 1 | 2016 | 751 | 0.020 | Why? |  | Comorbidity | 1 | 2017 | 1611 | 0.020 | Why? |  | Fatal Outcome | 1 | 2013 | 305 | 0.020 | Why? |  | Life Style | 1 | 2014 | 480 | 0.020 | Why? |  | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 151 | 0.020 | Why? |  | Immunologic Factors | 1 | 2014 | 239 | 0.020 | Why? |  | Dietary Supplements | 1 | 2016 | 560 | 0.020 | Why? |  | Connective Tissue Diseases | 1 | 2012 | 84 | 0.020 | Why? |  | Polymerase Chain Reaction | 1 | 2014 | 1061 | 0.020 | Why? |  | Erythrocytes | 1 | 2016 | 692 | 0.020 | Why? |  | Mutation | 1 | 2022 | 3948 | 0.020 | Why? |  | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 346 | 0.020 | Why? |  | Particulate Matter | 1 | 2013 | 313 | 0.020 | Why? |  | Environmental Monitoring | 1 | 2013 | 369 | 0.020 | Why? |  | Internet | 1 | 2014 | 652 | 0.020 | Why? |  | Exercise | 1 | 2021 | 2015 | 0.020 | Why? |  | Overweight | 1 | 2014 | 554 | 0.020 | Why? |  | Body Composition | 1 | 2013 | 665 | 0.020 | Why? |  | Child | 3 | 2021 | 21896 | 0.020 | Why? |  | Interferon-gamma | 1 | 2012 | 790 | 0.020 | Why? |  | Self Report | 1 | 2013 | 827 | 0.020 | Why? |  | Ultrasonography | 1 | 2012 | 749 | 0.020 | Why? |  | Bottle Feeding | 1 | 2007 | 21 | 0.020 | Why? |  | Gene Expression Regulation | 1 | 2016 | 2615 | 0.020 | Why? |  | Algorithms | 1 | 2014 | 1695 | 0.020 | Why? |  | Histocompatibility Testing | 1 | 2007 | 126 | 0.020 | Why? |  | Diabetes Mellitus | 1 | 2015 | 1033 | 0.020 | Why? |  | Veterans | 1 | 2018 | 1446 | 0.020 | Why? |  | Hypertension | 1 | 2015 | 1291 | 0.020 | Why? |  | Uterine Cervical Neoplasms | 1 | 2007 | 253 | 0.010 | Why? |  | Siblings | 1 | 2005 | 228 | 0.010 | Why? |  | Tobacco Smoke Pollution | 1 | 2007 | 284 | 0.010 | Why? |  | Randomized Controlled Trials as Topic | 1 | 2007 | 1460 | 0.010 | Why? |  | Pain | 1 | 2007 | 834 | 0.010 | Why? |  | Arthritis, Infectious | 1 | 1994 | 63 | 0.010 | Why? |  | Child, Preschool | 1 | 2007 | 11013 | 0.010 | Why? |  | Diabetes Mellitus, Type 1 | 1 | 2006 | 3697 | 0.000 | Why? | 
 | 
																	
																		
																			
																					
    Deane's Networks
 
Click the "See All" links for more information and interactive visualizations!
 Concepts  Derived automatically from this person's publications._ Co-Authors  People in Profiles who have published with this person._ Similar People  People who share similar concepts with this person._ 
            
                Same Department   
				People who are also in this person's primary department.
			 Physical Neighbors  People whose addresses are nearby this person._ |